Document is current
Any future updates will be listed below
-
Authors
Chen, Rou-Zhen
Balaji, Sweta
Bozkurt, Selen
Wallach, Joshua D.
Parikh, Ravi B.
-
Funding
Funding for this research was provided by:
Arnold Ventures
- License Information
-
More Information
Article History
Received: 8 December 2025
Accepted: 6 February 2026
First Online: 19 February 2026
Declarations
:
: Ethical approval was not required for this scoping review.
: Not applicable.
: J.D.W. is supported by Arnold Ventures, the US Food and Drug Administration through the Yale-Mayo CERSI, Johnson & Johnson through the Yale Open Data Access project, and the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under awards 1K01AA028258 and 1R01AA032254 and previously served as a consultant to Hagens Berman Sobol Shapiro LLP and Dugan Law Firm APLC. R.B.P. discloses grants from the National Institutes of Health, Department of Defense, Prostate Cancer Foundation, NCCN Foundation, Humana, Emerson Collective, Schmidt Futures, Arnold Ventures, Mendel.ai, and Veterans Health Administration; personal fees and equity from GNS Healthcare, Thyme Care, Main Street Health, Optinosis, and Onc.AI; personal fees from ConcertAI, Cancer Study Group, Mendel.ai, Biofourmis, Archetype Therapeutics, CreditSuisse, G1 Therapeutics, Humana, and Nanology; stock options in Counsel Health; honoraria from Flatiron and Medscape; has board membership (unpaid) at the Coalition to Transform Advanced Care and American Cancer Society; editorship at the Journal of Clinical Oncology; and serving on a leadership consortium (unpaid) at the National Quality Forum, all outside the submitted work. All other authors have no competing interest to disclose.
